SEC-sourced researchBeta
LXRX
LEXICON PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0001062822
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 1,204,000.0000 | Mar 5, 2026 |
| December 2024 | 31,081,000.0000 | Mar 5, 2026 |
| December 2025 | 49,803,000.0000 | Mar 5, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 49,803,000.0000 | -50,341,000.0000 | -67,851,000.0000 | 184,987,000.0000 | 77,449,000.0000 | Mar 5, 2026 |
| December 2024 | 31,081,000.0000 | -200,403,000.0000 | -178,780,000.0000 | 298,420,000.0000 | 152,470,000.0000 | Mar 5, 2026 |
| December 2023 | 1,204,000.0000 | -177,119,000.0000 | -161,897,000.0000 | — | — | Mar 5, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $49.8M | December 2025 | Mar 5, 2026 | 10-K |
| Previous period revenueRevenues | $31.08M | December 2024 | Mar 5, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$50.34M | December 2025 | Mar 5, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$67.85M | December 2025 | Mar 5, 2026 | 10-K |
| Total assetsAssets | $184.99M | December 2025 | Mar 5, 2026 | 10-K |
| Total liabilitiesLiabilities | $77.45M | December 2025 | Mar 5, 2026 | 10-K |